<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308449</url>
  </required_header>
  <id_info>
    <org_study_id>13/SC/0439</org_study_id>
    <nct_id>NCT02308449</nct_id>
  </id_info>
  <brief_title>Iron Status and Human Metabolism</brief_title>
  <official_title>Effects of Endogenous Iron Status and Intravenous Iron on Human Skeletal Muscle Metabolism at Rest and During Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency is common in cardiorespiratory diseases and appears to contribute to a worse
      outcome. This human physiology study will examine the extent to which human skeletal muscle
      metabolism and exercise physiology are impaired by iron deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective double-blind randomised controlled study of the effect of endogenous
      iron status on skeletal muscle metabolism and exercise physiology. 32 healthy volunteers will
      take part, half of whom will be iron-deficient. The study involves a screening visit and two
      half-day visits during which assessments are performed. 50% of each group will be randomised
      to receive iron-repletion with ferric carboxymaltose at the end of the first experimental
      visit before returning to repeat identical assessments around one week later. This approach
      will make it possible to explore whether baseline differences in skeletal muscle metabolism
      are explained by differences in iron status per se, whilst controlling for any learning
      effect during participation in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phosphocreatine depletion during small muscle mass exercise</measure>
    <time_frame>36 minute long graded exercise test; performed at baseline and follow-up visits (approximately a week apart)</time_frame>
    <description>Degree of phosphocreatine depletion during graded exercise of calf muscle assessed using magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise test performance</measure>
    <time_frame>Hour long graded exercise test; performed at baseline and follow-up visits (approximately a week apart)</time_frame>
    <description>Blood lactate and cardiorespiratory parameters during moderate large skeletal muscle mass exercise, assessed with cardiopulmonary exercise testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle biopsy findings</measure>
    <time_frame>Immediately before and immediately after hour long cardiopulmonary exercise test, performed at baseline and follow-up visits (approximately a week apart)</time_frame>
    <description>Skeletal muscle characteristics, assessed by minimally-invasive muscle biopsy (not a compulsory part of the protocol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant reported symptoms</measure>
    <time_frame>At study screening visit compared to four weeks following infusion of iron or placebo</time_frame>
    <description>Measures of fatigue, restless-legs syndrome and well-being assessed by self-reported questionnaires</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Iron-deficient, given placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron-deficient, given iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron-replete, given placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron-replete, given iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride</description>
    <arm_group_label>Iron-deficient, given iron</arm_group_label>
    <arm_group_label>Iron-replete, given iron</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride (placebo)</intervention_name>
    <description>Infusion of 250 mL 0.9% sodium chloride</description>
    <arm_group_label>Iron-deficient, given placebo</arm_group_label>
    <arm_group_label>Iron-replete, given placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give informed consent for participation in the study

          -  Men and women aged 18 years or older and generally in good health

          -  For iron-deficient volunteers: ferritin ≤ 15 microg/L and transferrin saturation &lt; 16%

          -  For iron-replete volunteers: ferritin ≥ 20 microg/L and transferrin saturation ≥ 20%

        Exclusion Criteria:

          -  Haemoglobin &lt; 8.0 g/dL

          -  Haemoglobinopathy

          -  Iron overload, defined as ferritin &gt; 300 microg/L

          -  Hypoxaemia (SpO2 &lt; 94%) or significant co-morbidity that may affect haematinics,
             metabolic or ventilatory responses

          -  Iron supplementation or blood transfusion within the previous 6 weeks

          -  Pregnancy or breast feeding

          -  Inability to exercise isolated calf muscle using a pedal or on a bicycle ergometer

          -  Contraindication to magnetic resonance spectroscopy exposure such as metallic implant

          -  Contraindication to receiving intravenous ferric carboxymaltose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Robbins, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew C Frise, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oxford OCMR &amp; CCRF, John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Formenti F, Constantin-Teodosiu D, Emmanuel Y, Cheeseman J, Dorrington KL, Edwards LM, Humphreys SM, Lappin TR, McMullin MF, McNamara CJ, Mills W, Murphy JA, O'Connor DF, Percy MJ, Ratcliffe PJ, Smith TG, Treacy M, Frayn KN, Greenhaff PL, Karpe F, Clarke K, Robbins PA. Regulation of human metabolism by hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12722-7. doi: 10.1073/pnas.1002339107. Epub 2010 Jun 28.</citation>
    <PMID>20616028</PMID>
  </reference>
  <reference>
    <citation>Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, León-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009 Oct 7;302(13):1444-50. doi: 10.1001/jama.2009.1404.</citation>
    <PMID>19809026</PMID>
  </reference>
  <reference>
    <citation>Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008 Dec 15;586(24):5999-6005. doi: 10.1113/jphysiol.2008.160960. Epub 2008 Oct 27.</citation>
    <PMID>18955380</PMID>
  </reference>
  <reference>
    <citation>Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, Robbins PA. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 2006 Jul;3(7):e290.</citation>
    <PMID>16768548</PMID>
  </reference>
  <reference>
    <citation>Finch CA, Gollnick PD, Hlastala MP, Miller LR, Dillmann E, Mackler B. Lactic acidosis as a result of iron deficiency. J Clin Invest. 1979 Jul;64(1):129-37.</citation>
    <PMID>447849</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

